Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Benjamin Rolles
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Co
Conflicts of Interest The authors declare the following conflicts of interest: Amaya: Bristol Myers Squibb: Honoraria.
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database
|
Abstract Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated.
By Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Tulika Gupta, Jessica M. Stempel, Najla Al Ali, Amy E. DeZern, Mikkael Sekeres, Geoffrey L Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Michael Savona, Constantine N Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice Wang, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David A Sallman, Anoop K. Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, María Díez-Campelo, David Valcárcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Rami S. Komrokji, Amer M Zeidan, Hayley Hawkins, Namrata Sonia Chandhok, Ted M. Getz, Amyah C. Harris, Jaclynn Campos
|
Nature
Verified
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing - Leukemia
|
Abstract Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2P95H versus wild-type mice upon stress-induced erythropoiesis and identified that SRSF2 mutations correlate with reduced hemoglobin in JAK2-mutant patients with myeloproliferative neoplasms (MPN).
By Jonas S. Jutzi, Edie I. Crosse, Chulwoo Kim, Charles Laurore, Benjamin Rolles, Frederike Kramer, Azucena Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Sumit Rai, Timothy A Graubert, Robert Bradley, Ann Mullally, Anna E. Marneth, Bob van Gasteren, Anastasia Tishena
|
Nature
Verified
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms - Leukemia
|
Abstract While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene.
By Benjamin Rolles, Nathan Fergusson, Jan Philipp Bewersdorf, Julia M Keating, Cecelia Perkins, Matthew Schwede, James England, Marlise R. Luskin, Daniel DeAngelo, Shai Shimony, Mifra Faiz, Addison C. Hillerbrand, Chulwoo Kim, Lachelle D. Weeks, Lauren Waldman, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Raajit Rampal, Harrison K. Tsai, Jason Gotlib, Vikas Gupta, Maximilian Stahl, Ann Mullally
|
Nature
Verified
ZIP10 as a potential therapeutic target in acute myeloid leukaemia
INTRODUCTION Despite advancements in understanding myeloid malignancies, effectively treating patients with acute myeloid leukaemia (AML) remains a major challenge. Currently, about 40%–50% of all AML patients below 60 years of age relapse after first-line therapy.
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation | Blood Cancer Journal
Hematopoietic stem cell transplantation (HSCT) represents the standard treatment for patients with high or intermediate-2 risk (IPSS classification) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with intermediate or unfavorable risk (ELN classification) [1].
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response - Leukemia
Abstract Cancer is driven by somatic mutations that provide a fitness advantage. While targeted therapies often focus on the mutated gene or its direct downstream effectors, imbalances brought on by cell-state alterations may also confer unique vulnerabilities.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Benjamin
Contact Benjamin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack